This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:

• Compares traditional ultrasound with advanced imaging techniques.
• Examines AI-based approaches in patient classification.

The episode concludes with a forward-looking perspective on the future management of MASLD.

Faculty

• Thomas Berg (Moderator)
• Timm Denecke (Faculty)
• Juan-Manuel Pericàs (Faculty)
• Valérie Vilgrain (Faculty)

This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.

Related episodes

• EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
• EASL Studio S6E1: Do we solve MASLD by treating obesity?
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

All EASL Studio Podcasts are available on EASL Campus.